Cart
sales@molnova.com
PVZB-1194
CAS No. 1141768-04-8
PVZB-1194( PVZB1194 )
Catalog No. M10501 CAS No. 1141768-04-8
PVZB-1194 is a bis(hetero)aryl derivative that inhibits kinesin spindle protein (KSP) ATPase witn IC50 of 0.12 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePVZB-1194
-
NoteResearch use only, not for human use.
-
Brief DescriptionPVZB-1194 is a bis(hetero)aryl derivative that inhibits kinesin spindle protein (KSP) ATPase witn IC50 of 0.12 uM.
-
DescriptionPVZB-1194 is a bis(hetero)aryl derivative that inhibits kinesin spindle protein (KSP) ATPase witn IC50 of 0.12 uM; inhibits HeLa cell proliferation with IC50 of 5.5 uM; potently inhibits KSP in a microruble dependent manner and induces a monoastral phenotype to arrest mitotic progression, abnormal KSP localization.
-
In Vitro——
-
In Vivo——
-
SynonymsPVZB1194
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetKinesin
-
RecptorKinesin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1141768-04-8
-
Formula Weight319.274
-
Molecular FormulaC13H9F4NO2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (783.04 mM)
-
SMILES——
-
Chemical Name4-[3-fluoro-4-(trifluoromethyl)phenyl]benzenesulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Matsuno K, et al. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1058-61.
2. Yokoyama H, et al. ACS Chem Biol. 2015 Apr 17;10(4):1128-36.
molnova catalog
related products
-
MAC1
MAC1 (Monastrol Antagonizing Compound 1) is a small molecule that can rescue spindle bipolarity in cells lacking Eg5 activity.
-
SB-743921
SB-743921 is a potent, selective kinesin spindle protein (KSP) inhibitor with Ki of 0.1 nM.
-
Mps1-IN-3
Mps1-IN-3 is an effective and selective inhibitor of MPS1 kinase (IC50: 50 nM).
